Zenas Biopharma Inks Sizable $300M Obexelimab Agreement
Royalty Pharma will provide up to $300 million in non-dilutive funding to Zenas Biopharma in exchange for a 5.5%...
eClinical Tech News
Charm Therapeutics Soars with $80M for Breakthrough AML Drug
Charm Therapeutics has closed an oversubscribed $80 million Series B co-led by NEA and SR One to advance an...
Charm Therapeutics Soars with $80M for AML Drug Development
Charm Therapeutics has closed an $80 million oversubscribed Series B, co-led by NEA and SR One, to advance its...
FDA Approves Leqembi Subcutaneous Injection for Alzheimer’s
FDA has approved Eisai and Biogen’s Leqembi iqlik, a once-weekly 360 mg subcutaneous autoinjector for maintenance dosing after 18...
Hernexeos® Approved in China for HER2-Mutant Lung Cancer
Boehringer Ingelheim has secured accelerated approval in China for HERNEXEOS (zongertinib) as monotherapy for adults with unresectable, locally advanced,...
Charm’s Successful $80M Round Fuels AML Drug Development
Charm Therapeutics has closed an oversubscribed $80 million Series B co-led by New Enterprise Associates and SR One to...
First Oral Therapy for HER2-Mutant NSCLC Approved in China
China’s National Medical Products Administration has granted accelerated, conditional approval to Boehringer Ingelheim’s Hernexeos (zongertinib) as monotherapy for adults...
PCI Biotech: Unveiling The 2025 Half-Year Interim Report
PCI Biotech has halted development of its photochemical lysis platform for viral vector manufacturing and signaled a going-concern risk...
Mesoblast’s Remarkable Year: FDA Approves Ryoncil® Launch
Mesoblast reported its fiscal 2025 results and, more importantly for the market, its first quarter of commercial sales for...
Rakovina Therapeutics Announces New Q2 Financial Results Update
Rakovina Therapeutics reported a Q2 2025 net loss of $2.9 million. It ended the quarter with $1.88 million in...